Core Viewpoint - Analysts expect Eli Lilly (LLY) to report quarterly earnings of $5.61 per share, reflecting a year-over-year increase of 43.1%, with revenues projected at $14.75 billion, up 30.5% from the previous year [1] Earnings Projections - The consensus EPS estimate has been revised downward by 1.5% in the past 30 days, indicating a reassessment by analysts [1][2] Key Metrics Forecast - Analysts predict 'Net Sales- Cyramza' at $246.20 million, a decrease of 1.1% year-over-year [4] - 'Net Sales- Humulin' is expected to be $206.10 million, down 7.8% year-over-year [4] - 'Net Sales- Humalog' is projected at $609.52 million, reflecting a decline of 3.5% from the previous year [4] - 'Net Sales- Forteo' is estimated at $62.76 million, down 10.2% year-over-year [5] - 'Net Sales- International-Forteo' is forecasted at $34.28 million, a decrease of 11% [5] - 'Net Sales- Cyramza (ROW)' is expected to reach $130.32 million, down 1.9% year-over-year [6] - 'Net Sales- Emgality (ROW)' is projected at $42.01 million, indicating a significant decline of 22.8% [6] - 'Net Sales- International-Alimta' is estimated at $17.05 million, down 20.3% from the previous year [6] - 'Net Sales- US-Humulin' is expected to be $154.98 million, down 8.5% year-over-year [7] - 'Net Sales- Emgality (US)' is projected at $135.67 million, reflecting a decrease of 1.4% [7] - 'Net Sales- US-Humalog' is estimated at $412.17 million, down 5.2% year-over-year [7] - 'Net Sales- US-Forteo' is expected to reach $28.73 million, indicating a decline of 8.8% [8] Stock Performance - Over the past month, shares of Lilly have returned -2.4%, contrasting with the Zacks S&P 500 composite's +0.6% change [8]

Core Insights - Eli Lilly reported a revenue of $12.73 billion for the quarter ended March 2025, marking a 45.2% increase year-over-year, with an EPS of $3.34 compared to $2.58 in the same quarter last year [1] - The revenue exceeded the Zacks Consensus Estimate of $12.62 billion by 0.86%, while the EPS fell short of the consensus estimate of $3.52 by 5.11% [1] Financial Performance - Key metrics indicate that Eli Lilly's shares have returned +9.9% over the past month, contrasting with a -0.7% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3] Sales Breakdown - Verzenio in the U.S. generated net sales of $657.60 million, below the average estimate of $720.57 million, reflecting a year-over-year increase of 3% [4] - Neuroscience products in the U.S. achieved net sales of $189.30 million, slightly above the average estimate of $188.66 million, with a year-over-year growth of 16% [4] - Geographic revenue from the U.S. reached $8.49 billion, slightly below the $8.50 billion estimate, representing a 49.1% year-over-year increase [4] - Humalog's net sales were $335.10 million, below the average estimate of $361.22 million, showing a year-over-year decline of 1% [4] - Cyramza's total net sales were $224.90 million, slightly below the estimate of $227.45 million, with a year-over-year decrease of 2.2% [4] - Humulin's net sales were $173.20 million, significantly below the estimate of $203.01 million, reflecting a 16% year-over-year decline [4] - Forteo's net sales were $66.60 million, exceeding the average estimate of $50.84 million, with an 8.7% year-over-year increase [4] - Erbitux's net sales were $149 million, slightly above the estimate of $146.04 million, indicating a 3% year-over-year increase [4] - Alimta's net sales were $28.20 million, significantly below the estimate of $46.13 million, showing a 59.4% year-over-year decline [4] - Other pharmaceuticals generated net sales of $212.90 million, slightly below the estimate of $213.18 million, reflecting a 12% year-over-year decline [4] - Oncology products achieved net sales of $1.95 billion, below the average estimate of $2.07 billion, with a year-over-year increase of 7.6% [4]